Sareum Holdings (SAR) RNS Announcements

Add to Alert list
Date Time Source Announcement
13 Nov 2026 07:00 AM
RNS
Notice of AGM, Annual Report and Accounts
06 Nov 2026 03:35 PM
RNS
Director Subs, Admission and Total Voting Rights
02 Nov 2026 07:00 AM
RNS
Preliminary Results for Year Ended 30 June 2026
30 Oct 2026 01:16 PM
RNS
Notice of Results and Investor Presentation
28 Oct 2026 07:00 AM
RNS
Results of WRAP Offer
27 Oct 2026 01:49 PM
RNS
Early Close of WRAP Retail Offer
26 Oct 2026 07:30 AM
RNS
Capital Access Window - Sareum Holdings Plc
26 Oct 2026 07:01 AM
RNS
WRAP Retail Offer for up to £100,000
26 Oct 2026 07:00 AM
RNS
Fundraise, Retail Offer and AIM Restoration
08 Oct 2026 07:30 AM
RNS
Capital Access Window - Sareum Holdings Plc
08 Oct 2026 07:00 AM
RNS
Capital Access Window
02 Sep 2026 05:29 PM
RNS
Exercise of Warrants
19 Aug 2026 02:19 PM
RNS
Exercise of Warrants
07 Aug 2026 01:28 PM
RNS
Exercise of Warrants
20 Jul 2026 07:00 AM
RNS
Completion of Dosing in Toxicology Programme
22 Jun 2026 09:40 AM
RNS
Publication of Phase 1 data on SDC-1801 in BJCP
01 May 2026 07:00 AM
RNS
Exercise of Warrants
12 Mar 2026 07:00 AM
RNS
Half-Year Report for Six Months Ended 31 Dec 2025
03 Mar 2026 07:00 AM
RNS
Notice of Results and Investor Presentation
17 Feb 2026 07:00 AM
RNS
Restart of Phase 2-enabling toxicology programme
23 Jan 2026 04:36 PM
RNS
Form 8.3 - Oxford Biomedica plc
09 Dec 2025 04:25 PM
RNS
Results of AGM
09 Dec 2025 07:00 AM
RNS
Annual General Meeting Statement
17 Nov 2025 07:00 AM
RNS
Notice of AGM, Annual Report and Accounts
30 Oct 2025 07:00 AM
RNS
Appointment of Joint Corporate Broker
23 Oct 2025 07:00 AM
RNS
Preliminary Results for Year Ended 30 June 2025
10 Oct 2025 07:00 AM
RNS
Update on toxicology study for SDC-1801
07 Oct 2025 07:00 AM
RNS
Notice of Results and Investor Presentation
26 Sep 2025 03:12 PM
RNS
Exercise of Warrants
18 Sep 2025 12:59 PM
RNS
Exercise of Warrants
26 Aug 2025 07:00 AM
RNS
Exercise of Warrants
20 Aug 2025 10:01 AM
RNS
Exercise of Warrants
12 Aug 2025 07:00 AM
RNS
Sareum Collaboration with Receptor.AI
09 Jul 2025 07:00 AM
RNS
Exercise of Warrants
04 Jul 2025 07:00 AM
RNS
Appointment of Sole Broker
29 May 2025 07:00 AM
RNS
Initiation of Toxicology Studies for SDC-1801
28 Apr 2025 07:00 AM
RNS
Update on TYK2/JAK1 and SRA737 Programmes
24 Apr 2025 07:00 AM
RNS
Exercise of Warrants
27 Mar 2025 07:00 AM
RNS
Director’s Dealing
25 Mar 2025 07:00 AM
RNS
Sareum Half-Year Report
20 Mar 2025 07:00 AM
RNS
Notice of HY Results and Investor Presentation
13 Mar 2025 07:15 AM
RNS
Institutional Equity Fundraise
13 Mar 2025 07:08 AM
RNS
Sareum Acquires Licence for SRA737
31 Dec 2024 07:00 AM
RNS
Update on SRA737
19 Dec 2024 04:07 PM
RNS
Results of AGM
19 Dec 2024 07:00 AM
RNS
AGM Statement
18 Dec 2024 07:00 AM
RNS
Appointment of Joint Broker
17 Dec 2024 09:14 AM
RNS
Holding(s) in Company
16 Dec 2024 07:00 AM
RNS
Award of Share Options
27 Nov 2024 09:38 AM
RNS
Notice of AGM, Annual Report and Accounts

Sareum is a clinical-stage drug discovery and development company that produces targeted small-molecule therapeutics for treating cancer and autoimmune diseases.

The drug research programs of the company are based on its proprietary drug discovery technology. The company delivers drug candidates for licensing to biotechnology and pharmaceutical companies at the pre-clinical or early clinical trials stage. 

SAR share price listed on AIM in 2004 under the ticker SAR.

UK 100

Latest directors dealings